San Clemente, Calif.-based ophthalmic medical technology company Glaukos Corp. announced on Dec. 27 it has submitted a pre-market approval application to US FDA for its minimally invasive glaucoma surgery (MIGS) iStent inject device used for treating glaucoma.
Glaukos pioneered MIGS devices, which are among the fastest-growing technologies for treating refractive mild to moderate glaucoma by reducing intraocular...







